APA

Goepfert, Fu B., Chabanon A., Bonaparte M. I., Davis M. G., Essink B. J., Frank I., Haney O., Janosczyk H., Keefer M. C., Koutsoukos M., Kimmel M. A., Masotti R., Savarino S. J., Schuerman L., Schwartz H., Sher L. D., Smith J., Tavares-Da-Silva F., Gurunathan S., Granados C. A. D. & de Bruyn G.Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. : .

Chicago

Goepfert, Fu Bo, Chabanon Anne-Laure, Bonaparte Matthew I, Davis Matthew G, Essink Brandon J, Frank Ian, Haney Owen, Janosczyk Helene, Keefer Michael C, Koutsoukos Marguerite, Kimmel Murray A, Masotti Roger, Savarino Stephen J, Schuerman Lode, Schwartz Howard, Sher Lawrence D, Smith Jon, Tavares-Da-Silva Fernanda, Gurunathan Sanjay, Granados Carlos A Diaz and de Bruyn Guy.Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. : .

Harvard

Goepfert, Fu B., Chabanon A., Bonaparte M. I., Davis M. G., Essink B. J., Frank I., Haney O., Janosczyk H., Keefer M. C., Koutsoukos M., Kimmel M. A., Masotti R., Savarino S. J., Schuerman L., Schwartz H., Sher L. D., Smith J., Tavares-Da-Silva F., Gurunathan S., Granados C. A. D. and de Bruyn G.Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. : .

MLA

Goepfert, Fu Bo, Chabanon Anne-Laure, Bonaparte Matthew I, Davis Matthew G, Essink Brandon J, Frank Ian, Haney Owen, Janosczyk Helene, Keefer Michael C, Koutsoukos Marguerite, Kimmel Murray A, Masotti Roger, Savarino Stephen J, Schuerman Lode, Schwartz Howard, Sher Lawrence D, Smith Jon, Tavares-Da-Silva Fernanda, Gurunathan Sanjay, Granados Carlos A Diaz and de Bruyn Guy.: . .